This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baldwin, D. S. Search for Related Content PubMed PubMed Citation Articles by Baldwin, D. S. Social Bookmarking                         What's this?

A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment

Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, Southampton; University Department of Psychiatry Royal South Hants Hospital Graham Road Southampton UK; dsb{at}soton.ac.uk

Christopher J. Hawley

Hertfordshire Neuroscience Research Group, University of Hertfordshire, Hertfordshire

Karen Mellors

Bristol-Myers Squibb Company, Hounslow, Middlesex, UK

On behalf of the CN104-070 study group

We investigated the safety, tolerability and efficacy of nefazodone and paroxetine in the continuation phase of treatment of depression. The study comprised a double-blind, parallel-group comparison over 4 months, of patients who had previously improved following random allocation to nefazodone or paroxetine during an 8-week acute treatment study. Assessments included Clinical Global Impression Scales, Hamilton Rating Scales for Depression and Anxiety, Montgomery-Asberg Depression Rating Scale and the Patient Global Assessment Scale, in addition to a review of reported adverse events, vital sign measurements, electrocardiograms and clinical laboratory tests. One hundred and eight patients participated in the continuation study (53 received paroxetine, 55 nefazodone) and 73 completed treatment. No clinically relevant differences in antidepressant efficacy were seen. Headache and somnolence were the most common reported adverse events in both treatment groups. Both nefazodone and paroxetine maintain their efficacy in continuation treatment, and both are generally well tolerated.

Key Words: continuation treatment • major depression • nefazodone • paroxetine

Journal of Psychopharmacology, Vol. 15, No. 3, 161-165 (2001)
DOI: 10.1177/026988110101500303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. G. Blazer Depression in Late Life: Review and Commentary Focus, January 1, 2009; 7(1): 118 - 136. [Abstract] [Full Text] [PDF]

				D. G. Blazer Depression in Late Life: Review and Commentary J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2003; 58(3): M249 - 265. [Abstract] [Full Text] [PDF]